Clinical Trial Update: Pyruvate Kinase Isoform M2 (PKM2) as a Possible Biomarker for Cancer

View source ↗

Summary

A completed clinical trial evaluated PKM2 as a potential biomarker for cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Cancer | Status: COMPLETED